JP2017119701A - バイオ医薬の送達のためのエキソソーム - Google Patents
バイオ医薬の送達のためのエキソソーム Download PDFInfo
- Publication number
- JP2017119701A JP2017119701A JP2017000739A JP2017000739A JP2017119701A JP 2017119701 A JP2017119701 A JP 2017119701A JP 2017000739 A JP2017000739 A JP 2017000739A JP 2017000739 A JP2017000739 A JP 2017000739A JP 2017119701 A JP2017119701 A JP 2017119701A
- Authority
- JP
- Japan
- Prior art keywords
- exosome
- peptide
- protein
- antibody
- exosomes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 192
- 238000012384 transportation and delivery Methods 0.000 title description 19
- 229940126587 biotherapeutics Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 117
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 90
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 89
- 210000004027 cell Anatomy 0.000 claims abstract description 64
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 38
- 239000012634 fragment Substances 0.000 claims abstract description 30
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 24
- 239000000427 antigen Substances 0.000 claims abstract description 22
- 108091007433 antigens Proteins 0.000 claims abstract description 22
- 102000036639 antigens Human genes 0.000 claims abstract description 22
- 238000004520 electroporation Methods 0.000 claims abstract description 17
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 13
- 201000011510 cancer Diseases 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 210000000056 organ Anatomy 0.000 claims abstract description 5
- 206010052779 Transplant rejections Diseases 0.000 claims abstract description 3
- 230000008685 targeting Effects 0.000 claims description 50
- 102000035160 transmembrane proteins Human genes 0.000 claims description 21
- 108091005703 transmembrane proteins Proteins 0.000 claims description 21
- 238000011068 loading method Methods 0.000 claims description 18
- 101150117895 LAMP2 gene Proteins 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 8
- -1 CD86 Proteins 0.000 claims description 7
- 230000001363 autoimmune Effects 0.000 claims description 5
- 238000001890 transfection Methods 0.000 claims description 5
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 4
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 4
- 101150048357 Lamp1 gene Proteins 0.000 claims description 4
- 108010010469 Qa-SNARE Proteins Proteins 0.000 claims description 4
- 102000047466 Syntaxin-3 Human genes 0.000 claims description 4
- 125000002091 cationic group Chemical group 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 102000010660 flotillin Human genes 0.000 claims description 3
- 108060000864 flotillin Proteins 0.000 claims description 3
- 238000001638 lipofection Methods 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 abstract description 6
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 76
- 102000004196 processed proteins & peptides Human genes 0.000 description 42
- 235000001014 amino acid Nutrition 0.000 description 34
- 150000001413 amino acids Chemical class 0.000 description 29
- 229960000074 biopharmaceutical Drugs 0.000 description 15
- 108020001507 fusion proteins Proteins 0.000 description 15
- 102000037865 fusion proteins Human genes 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 108010081400 fluorescein isothiocyante avidin Proteins 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 239000012096 transfection reagent Substances 0.000 description 6
- 108010062760 transportan Proteins 0.000 description 6
- 108010004729 Phycoerythrin Proteins 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 210000002487 multivesicular body Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 108010041012 Integrin alpha4 Proteins 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 101710197241 Accessory gland-specific peptide 70A Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 102000004379 Adrenomedullin Human genes 0.000 description 1
- 101800004616 Adrenomedullin Proteins 0.000 description 1
- SITWEMZOJNKJCH-WDSKDSINSA-N Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SITWEMZOJNKJCH-WDSKDSINSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102000009565 Lysosomal-Associated Membrane Protein 2 Human genes 0.000 description 1
- 108010009491 Lysosomal-Associated Membrane Protein 2 Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 102100028927 Secretin receptor Human genes 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- DESSEGDLRYOPTJ-VRANXALZSA-N biphalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NNC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 DESSEGDLRYOPTJ-VRANXALZSA-N 0.000 description 1
- 108010033394 biphalin Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 108700023159 delta Opioid Receptors Proteins 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 108700027603 secretin receptor Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
【解決手段】例えば樹状細胞に由来するエキソソームを含む組成物であって、エキソソームには外因性タンパク質及び/又はペプチドがエレクトロポレーション等の方法によって搭載されている組成物。前記タンパク質及び/又はペプチドは抗体又はその抗原結合フラグメントであることが好ましい。
【選択図】なし
Description
本明細書で記載されているように、好ましい実施形態において、エキソソームに組み込まれるタンパク質及び/又はペプチドは抗体又は抗体フラグメントである。本明細書において、「抗体」という語は、抗体全体及び任意の抗原結合フラグメント(すなわち「抗原結合部位」)又はそれらの単鎖を包含する。抗体とは、ジスルフィド結合で相互に連結された少なくとも2つの重(H)鎖及び2つの軽(L)鎖、又はそれらの抗原結合部分を含む糖タンパク質を指す。各重鎖は、重鎖可変領域(本明細書ではVHと略記)及び重鎖定常領域で構成される。各軽鎖は、軽鎖可変領域(本明細書ではVLと略記)及び軽鎖定常領域で構成される。重度及び軽鎖の可変領域は、抗原と相互作用する結合ドメインを含む。VH及びVL領域は、より高度に保存された領域(フレームワーク領域(FR)と呼ばれる。)が散在した超可変領域(相補性決定領域(CDR)と呼ばれる。)にさらに分類することができる。
本発明のエキソソームは所望の細胞型又は組織に対してターゲティングされ得る。このターゲティングは、標的となる細胞の表面で発現する細胞表面部分に結合するターゲティング部分をエキソソームの表面で発現させることによって達成される。典型的には、ターゲティング部分は、エキソソームの表面で通常発現する膜貫通タンパク質との融合タンパク質として発現するペプチドである。
本発明の構築物は任意の適切な方法によって投与され得る。ヒト又は動物の対象に対する投与は、非経口、筋肉内、脳内、血管内(例えば静脈内)、皮下、鼻腔内、心臓内、脳室内、腹腔内又は経皮投与から選択され得る。典型的には、送達の方法は注射によるものである。好ましくは、注射は筋肉内又は血管内(例えば静脈内)注射である。医師は、個々の患者ごとに必要とされる投与経路を決定することができる。
エレクトロポレーション緩衝液(1.15mMリン酸カリウム(pH7.2)、25mM KCl、21%オプティプレップ(Optiprep))中で、ヒト胎児由来腎臓細胞(HEK)エキソソームをフィコエリトリン(PE)結合ヤギ抗ウサギIgG抗体と混合し、ローディングされないままにする(抗体との混合は行ったが、エレクトロポレーションは行わない)か、又は200mVでエレクトロポレートした。次いで、抗体搭載エキソソームをHEK細胞に添加し、2時間インキュベートして575nmで蛍光を測定した。次いで、HEK細胞をリン酸緩衝生理食塩水(PBS)で洗浄し、画像化した。Figure1は、200mVでローディングされたエキソソーム(B)で細胞を処理した場合の、(抗体と混合されたが、エレクトロポレートされていない対照エキソソーム(A)と比較した)PE−抗体シグナルの細胞質内及び核内局在を示す。
ポリヌクレオチド配列:ggctggaccctgaacagcgcgggctatctgctgggcaaaattaacctgaaagcgctggcggcgctggcga aaaaaattctg(配列番号3)によってコードされたトランスポータンペプチド:GWTLNSAGYLLGKINLKALAALAKKIL(配列番号2)を、国際公開第2010/119256号に記載されたLamp2b発現ベクター内に挿入した。
2 Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi−Castagnoli P, Raposo G, Amigorena S (1998), Eradication of established murine tumors using a novel cell−free vaccine: dendritic cell−derived exosomes, Nat Med 4:594−600.
3 Hao S, Moyana T, Xiang J (2007), Review: cancer immunotherapy by exosome−based vaccines, Cancer Biother Radiopharm 22:692−703.
4 Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO (2007), Exosome−mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nat Cell Biol 9(6):654−9.
5 Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena−Esteves M, Curry WT Jr, Carter BS, Krichevsky AM, Breakefield XO (2008), Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers, Nat Cell Biol 10(12):1470−6.
6 WO2010/119256
実施形態1:
エキソソームを含む組成物であって、エキソソームには外因性タンパク質及び/又はペプチドが搭載されており、前記タンパク質及び/又はペプチドは抗体又はその抗原結合フラグメントである、組成物。
実施形態2:
エキソソームは樹状細胞に由来する、実施形態1に記載の組成物。
実施形態3:
前記タンパク質及び/又はペプチドは、ヒト又は動物の身体に治療を行う方法における使用のためのものである、実施形態1又は2に記載の組成物。
実施形態4:
前記タンパク質及び/又はペプチドは、癌、自己免疫状態、及び/又は臓器若しくは細胞移植拒絶反応の治療及び/又は予防における使用のためのものである、実施形態3に記載の組成物。
実施形態5:
エキソソームは、該エキソソームの表面で発現するターゲティング部分を含む、実施形態1〜4のいずれかに記載の組成物。
実施形態6:
前記ターゲティング部分は、標的となる細胞上に存在する部分に結合するペプチドを含む、実施形態5に記載の組成物。
実施形態7:
エキソソームは、前記ペプチドターゲティング部分を組み込むように修飾されたエキソソーム膜貫通タンパク質を含む、実施形態6に記載の組成物。
実施形態8:
エキソソーム膜貫通タンパク質は、Lamp−1、Lamp−2、CD13、CD86、フロチリン、及びシンタキシン−3から選択される、実施形態7に記載の組成物。
実施形態9:
エキソソーム膜貫通タンパク質はLamp−2bである、実施形態8に記載の組成物。
実施形態10:
前記抗体又はそのフラグメントはモノクローナル抗体又はそのフラグメントである、実施形態1〜9のいずれかに記載の組成物。
実施形態11:
エキソソームにタンパク質及び/又はペプチドを搭載する方法であって、エキソソームの組成物を用意するステップと、エレクトロポレーションによってエキソソームにタンパク質及び/又はペプチドを搭載するステップと、を含み、前記タンパク質及び/又はペプチドは抗体又はその抗原結合フラグメントである、方法。
実施形態12:
エレクトロポレーションは20〜100v/cmの電圧で行われる、又はエレクトロポレーションは200mVの電圧で行われる、実施形態11に記載の方法。
実施形態13:
エキソソームにタンパク質及び/又はペプチドを搭載する方法であって、エキソソームの組成物を用意するステップと、カチオン性リポソームトランスフェクション剤を使用して、トランスフェクションによってエキソソームにタンパク質及び/又はペプチドを搭載するステップと、を含み、前記タンパク質及び/又はペプチドは抗体又はその抗原結合フラグメントである、方法。
実施形態14:
前記抗体又はそのフラグメントはモノクローナル抗体又はそのフラグメントである、実施形態11〜13のいずれかに記載の方法。
実施形態15:
エキソソームは樹状細胞に由来する、実施形態11〜14のいずれかに記載の方法。
本発明は、以下の実施例を参照してより詳細に説明される。
Claims (15)
- エキソソームを含む組成物であって、エキソソームには外因性タンパク質及び/又はペプチドが搭載されており、前記タンパク質及び/又はペプチドは抗体又はその抗原結合フラグメントである、組成物。
- エキソソームは樹状細胞に由来する、請求項1に記載の組成物。
- 前記タンパク質及び/又はペプチドは、ヒト又は動物の身体に治療を行う方法における使用のためのものである、請求項1又は2に記載の組成物。
- 前記タンパク質及び/又はペプチドは、癌、自己免疫状態、及び/又は臓器若しくは細胞移植拒絶反応の治療及び/又は予防における使用のためのものである、請求項3に記載の組成物。
- エキソソームは、該エキソソームの表面で発現するターゲティング部分を含む、請求項1〜4のいずれか一項に記載の組成物。
- 前記ターゲティング部分は、標的となる細胞上に存在する部分に結合するペプチドを含む、請求項5に記載の組成物。
- エキソソームは、前記ペプチドターゲティング部分を組み込むように修飾されたエキソソーム膜貫通タンパク質を含む、請求項6に記載の組成物。
- エキソソーム膜貫通タンパク質は、Lamp−1、Lamp−2、CD13、CD86、フロチリン、及びシンタキシン−3から選択される、請求項7に記載の組成物。
- エキソソーム膜貫通タンパク質はLamp−2bである、請求項8に記載の組成物。
- 前記抗体又はそのフラグメントはモノクローナル抗体又はそのフラグメントである、請求項1〜9のいずれか一項に記載の組成物。
- エキソソームにタンパク質及び/又はペプチドを搭載する方法であって、エキソソームの組成物を用意するステップと、エレクトロポレーションによってエキソソームにタンパク質及び/又はペプチドを搭載するステップと、を含み、前記タンパク質及び/又はペプチドは抗体又はその抗原結合フラグメントである、方法。
- エレクトロポレーションは20〜100v/cmの電圧で行われる、又はエレクトロポレーションは200mVの電圧で行われる、請求項11に記載の方法。
- エキソソームにタンパク質及び/又はペプチドを搭載する方法であって、エキソソームの組成物を用意するステップと、カチオン性リポソームトランスフェクション剤を使用して、トランスフェクションによってエキソソームにタンパク質及び/又はペプチドを搭載するステップと、を含み、前記タンパク質及び/又はペプチドは抗体又はその抗原結合フラグメントである、方法。
- 前記抗体又はそのフラグメントはモノクローナル抗体又はそのフラグメントである、請求項11〜13のいずれか一項に記載の方法。
- エキソソームは樹状細胞に由来する、請求項11〜14のいずれか一項に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1121070.5 | 2011-12-07 | ||
GBGB1121070.5A GB201121070D0 (en) | 2011-12-07 | 2011-12-07 | composition for delivery of biotherapeutics |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014545356A Division JP6145595B2 (ja) | 2011-12-07 | 2012-12-07 | バイオ医薬の送達のためのエキソソーム |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019168435A Division JP2020023503A (ja) | 2011-12-07 | 2019-09-17 | バイオ医薬の送達のためのエキソソーム |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2017119701A true JP2017119701A (ja) | 2017-07-06 |
Family
ID=45541371
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014545356A Active JP6145595B2 (ja) | 2011-12-07 | 2012-12-07 | バイオ医薬の送達のためのエキソソーム |
JP2017000739A Pending JP2017119701A (ja) | 2011-12-07 | 2017-01-05 | バイオ医薬の送達のためのエキソソーム |
JP2019168435A Pending JP2020023503A (ja) | 2011-12-07 | 2019-09-17 | バイオ医薬の送達のためのエキソソーム |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014545356A Active JP6145595B2 (ja) | 2011-12-07 | 2012-12-07 | バイオ医薬の送達のためのエキソソーム |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019168435A Pending JP2020023503A (ja) | 2011-12-07 | 2019-09-17 | バイオ医薬の送達のためのエキソソーム |
Country Status (8)
Country | Link |
---|---|
US (2) | US11103586B2 (ja) |
EP (3) | EP2788019B1 (ja) |
JP (3) | JP6145595B2 (ja) |
CN (1) | CN104053451A (ja) |
DK (1) | DK2788019T3 (ja) |
ES (1) | ES2625863T3 (ja) |
GB (1) | GB201121070D0 (ja) |
WO (1) | WO2013084000A2 (ja) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5713325B2 (ja) | 2009-04-17 | 2015-05-07 | アイシス イノヴェイション リミテッド | 遺伝物質の送達用の組成物 |
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
HRP20220796T1 (hr) | 2010-10-01 | 2022-10-14 | ModernaTX, Inc. | Ribonukleinske kiseline koje sadrže n1-metil-pseudouracil i njihove uporabe |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3492109B1 (en) | 2011-10-03 | 2020-03-04 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
RS63244B1 (sr) | 2011-12-16 | 2022-06-30 | Modernatx Inc | Kompozicije modifikovane mrna |
WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
CA2889020A1 (en) | 2012-10-23 | 2014-05-01 | Cornell University | Treatment of metastatic breast cancer |
PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
JP6542197B2 (ja) | 2013-04-12 | 2019-07-10 | エヴォックス・セラピューティクス・リミテッド | 治療的送達小胞 |
WO2015041809A2 (en) | 2013-08-26 | 2015-03-26 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Small molecule cellular reprogramming to generate neuronal cells |
CA2923029A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015038585A1 (en) * | 2013-09-11 | 2015-03-19 | Trustees Of Dartmouth College | Method for selectively inhibiting acat1 in the treatment of alzheimer's disease |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
SG11201602503TA (en) | 2013-10-03 | 2016-04-28 | Moderna Therapeutics Inc | Polynucleotides encoding low density lipoprotein receptor |
EP3733856A1 (en) | 2014-04-18 | 2020-11-04 | University of Massachusetts | Exosomal loading using hydrophobically modified oligonucleotides |
EP3169693B1 (en) | 2014-07-16 | 2022-03-09 | ModernaTX, Inc. | Chimeric polynucleotides |
US20170210788A1 (en) | 2014-07-23 | 2017-07-27 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
EP3307890A1 (en) * | 2015-06-10 | 2018-04-18 | Board of Regents, The University of Texas System | Use of exosomes for the treatment of disease |
KR20180086440A (ko) | 2015-11-18 | 2018-07-31 | 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 | 신경 세포 세포외 소포체 |
RS63135B1 (sr) | 2015-12-23 | 2022-05-31 | Modernatx Inc | Postupci upotrebe polinukleotida koji kodiraju ox40 ligand |
US20190241658A1 (en) | 2016-01-10 | 2019-08-08 | Modernatx, Inc. | Therapeutic mRNAs encoding anti CTLA-4 antibodies |
WO2017175253A1 (ja) * | 2016-04-04 | 2017-10-12 | 国立研究開発法人医薬基盤・健康・栄養研究所 | エキソソーム標的dnaワクチン |
EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
GB201609216D0 (en) * | 2016-05-25 | 2016-07-06 | Evox Therapeutics And Isis Innovation Ltd | Exosomes comprising therapeutic polypeptides |
GB2552460A (en) | 2016-07-11 | 2018-01-31 | Evox Therapeutics Ltd | CPP-Mediated EV Loading |
GB2552301A (en) * | 2016-07-11 | 2018-01-24 | Evox Therapeutics Ltd | Metabolic drug loading of EVs |
GB2552774A (en) * | 2016-07-12 | 2018-02-14 | Evox Therapeutics Ltd | EV-Mediated delivery of binding protein-small molecule conjugates |
GB2552473A (en) | 2016-07-21 | 2018-01-31 | Evox Therapeutics Ltd | Surface decoration of extracellular vesicles |
AU2017322522B2 (en) * | 2016-09-09 | 2024-01-04 | Cornell University | Delivery of nucleic acids, proteins and small molecules in vitreous vesicular bodies |
GB201702863D0 (en) | 2017-02-22 | 2017-04-05 | Evox Therapeutics Ltd | Improved loading of EVs with therapeutic proteins |
IL270496B1 (en) | 2017-05-08 | 2024-07-01 | Flagship Pioneering Innovations V Inc | Intra-membrane aid preparations and their uses |
JP7285220B2 (ja) | 2017-05-18 | 2023-06-01 | モデルナティエックス インコーポレイテッド | 連結したインターロイキン-12(il12)ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 |
ES2962985T3 (es) | 2017-06-15 | 2024-03-22 | Univ Chicago | Composiciones para el tratamiento del cáncer |
EP3652349A1 (en) | 2017-07-10 | 2020-05-20 | Cornell University | Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatment |
US11938219B2 (en) * | 2017-07-29 | 2024-03-26 | University Of Southern California | Synthetic extracellular vesicles for novel therapies |
US11612618B2 (en) | 2017-11-14 | 2023-03-28 | Henry Ford Health System | Compositions for use in the treatment and prevention of cardiovascular disorders resulting from cerebrovascular injury |
JP7253762B2 (ja) * | 2017-12-27 | 2023-04-07 | 慈濟大學 | タンパク質を表面に発現させた小胞によるオートファジー細胞およびアポトーシス細胞への薬剤送達 |
KR102143160B1 (ko) * | 2018-01-15 | 2020-08-10 | 연세대학교 산학협력단 | 심장 표적 단백질을 함유한 마이크로베지클을 포함하는 활성 성분을 심장에 전달하기 위한 약학적 조성물 및 이를 이용한 방법 |
US20210030850A1 (en) * | 2018-04-10 | 2021-02-04 | Northwestern University | Extracellular vesicles comprising targeting affinity domain-based membrane proteins |
EP3598978B1 (en) * | 2018-07-26 | 2024-05-29 | EXOFIX S.r.l. | Fibroadipogenic progenitor-derived exosomes for regeneration of dystrophic muscles |
WO2020026001A1 (es) * | 2018-07-31 | 2020-02-06 | Pineda Olvera Benjamin | Vacunación con microvesículas derivadas de células tumorales para tratamiento de cáncer |
US20210238552A1 (en) | 2018-08-10 | 2021-08-05 | Unicyte Ev Ag | Extracellular vesicles loaded with an exogenous molecule |
US20210348114A1 (en) * | 2018-08-24 | 2021-11-11 | University Of Delaware | Extracellular vesicles as biomarkers and therapeutics for neuromuscular disorders |
WO2020069313A2 (en) | 2018-09-28 | 2020-04-02 | Henry Ford Health System | Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke |
EP3920950A1 (en) | 2019-02-08 | 2021-12-15 | CureVac AG | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
EP3946269A4 (en) * | 2019-03-27 | 2023-05-03 | University of Georgia Research Foundation, Inc. | METHODS FOR MAKING TARGETED VESICLES, AND COMPOSITIONS SO MADE |
EP3947641A4 (en) * | 2019-03-28 | 2022-05-25 | AgeX Therapeutics, Inc. | INDUCED TISSUE REGENERATION USING EXTRACELLULAR VESICLES |
US20240024220A1 (en) * | 2019-05-11 | 2024-01-25 | Youngsuk Yi | Neurotoxin compositions and methods |
IL296612A (en) * | 2020-03-20 | 2022-11-01 | Orgenesis Inc | Ribonucleases for the treatment of viral infections |
EP4132479A1 (en) | 2020-04-07 | 2023-02-15 | Ramot at Tel-Aviv University Ltd. | Cannabidiol-containing compositions and uses thereof |
US20210330760A1 (en) * | 2020-04-22 | 2021-10-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and materials for treating osteoarthritis |
KR102341138B1 (ko) | 2020-05-31 | 2021-12-21 | 주식회사 엑소코바이오 | 엑소좀의 막단백질 변이체를 포함하는 엑소좀 및 이의 제조방법 |
WO2022023559A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
WO2022149779A1 (ko) * | 2021-01-11 | 2022-07-14 | 주식회사 엑소코바이오 | 과발현된 Fc 수용체 또는 이의 일부를 포함하는 엑소좀 및 이의 제조방법 |
KR20220101559A (ko) | 2021-01-11 | 2022-07-19 | 주식회사 엑소코바이오 | 과발현된 Fc 수용체 또는 이의 일부를 포함하는 엑소좀 및 이의 제조방법 |
CN116997651A (zh) | 2021-01-19 | 2023-11-03 | J·大卫格莱斯顿研究所-根据J·大卫格莱斯顿遗嘱的遗嘱信托 | 用于增强人t细胞功能的基因激活靶标 |
KR20220106696A (ko) | 2021-01-21 | 2022-07-29 | 주식회사 엑소코바이오 | 목적 단백질 또는 펩타이드가 융합가능한 Fc 수용체 또는 이의 일부를 포함하는 재조합 엑소좀 및 이의 용도 |
CN114874990A (zh) * | 2021-02-05 | 2022-08-09 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种功能化外泌体及其制备方法和应用 |
WO2022215078A1 (en) * | 2021-04-07 | 2022-10-13 | Ramot At Tel-Aviv University Ltd. | Modified cannabinoids and uses thereof |
EP4320242A1 (en) | 2021-04-08 | 2024-02-14 | Sana Biotechnology, Inc. | Cd8-specific antibody constructs and compositions thereof |
US11180534B1 (en) * | 2021-06-04 | 2021-11-23 | Morehouse School Of Medicine | Compositions and methods for treating SARS-CoV-2 infections |
WO2023133422A1 (en) * | 2022-01-04 | 2023-07-13 | The Broad Institute, Inc. | Compositions and methods for delivering cargo to a target cell |
WO2023176750A1 (ja) * | 2022-03-15 | 2023-09-21 | 株式会社プロジェニサイトジャパン | 目的とする核酸を搭載した、核酸医薬品としてのエクソソームの新規製造方法 |
CN117802045A (zh) * | 2022-09-30 | 2024-04-02 | 北京恩康医药有限公司 | 一种工程化细胞外囊泡的构建及其应用 |
WO2024097418A2 (en) | 2022-11-03 | 2024-05-10 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Gene activation and interference targets for exhaustion/dysfunction-resistant t cell products and uses thereof |
WO2024186630A1 (en) | 2023-03-03 | 2024-09-12 | Henry Ford Health System | Use of extracellular vesicles for the treatment of cancer |
NL2034796B1 (en) * | 2023-05-10 | 2024-01-09 | Univ Henan Science & Tech | Preparation method and application of fluorescent-labeled exosomes |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003531864A (ja) * | 2000-04-27 | 2003-10-28 | アノシス・インコーポレーテッド | 膜小胞を生成する方法 |
JP2006518219A (ja) * | 2003-02-18 | 2006-08-10 | マックスサイト インコーポレーティッド | 電気穿孔法による細胞への抗原の負荷方法 |
WO2010119256A1 (en) * | 2009-04-17 | 2010-10-21 | Isis Innovation Limited | Composition for delivery of genetic material |
WO2010126081A1 (ja) * | 2009-05-01 | 2010-11-04 | 株式会社メディネット | 不溶性蛋白質及び/又はペプチドの可溶化方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4203413C2 (de) | 1992-02-06 | 1993-11-25 | Fraunhofer Ges Forschung | Mehrfachabtastungsverfahren |
AU6632496A (en) | 1995-08-03 | 1997-03-05 | Rijksuniversiteit Te Leiden | Cell derived antigen presenting vesicles |
US6669835B1 (en) | 1997-02-18 | 2003-12-30 | Atofina Chemicals, Inc. | Aqueous dispersions of polymerizable reactants and a water incompatible catalyst sorbed on an inorganic particulate carrier |
FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
US6645490B2 (en) | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
FR2785543B1 (fr) | 1998-11-05 | 2003-02-28 | Inst Nat Sante Rech Med | Exosomes modifies et utilisations |
US6627421B1 (en) * | 1999-04-13 | 2003-09-30 | Imarx Therapeutics, Inc. | Methods and systems for applying multi-mode energy to biological samples |
GB9927320D0 (en) | 1999-11-18 | 2000-01-12 | Chiron Spa | Exosome separation |
FR2812813B1 (fr) | 2000-08-09 | 2004-11-26 | Neovacs | Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires induits par des facteurs extracellulaires |
US7704964B2 (en) * | 2001-08-17 | 2010-04-27 | Exothera L.L.C. | Methods and compounds for the targeting of protein to exosomes |
KR100519384B1 (ko) | 2002-08-13 | 2005-10-06 | (주)누백스 | 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도 |
US7914792B2 (en) | 2003-02-14 | 2011-03-29 | Exothera L.L.C. | Methods and compounds for raising antibodies and for screening antibody repertoires |
US20050153304A1 (en) * | 2003-04-10 | 2005-07-14 | Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Multivariate profiling of complex biological regulatory pathways |
EP1537858A1 (en) | 2003-12-04 | 2005-06-08 | Vectron Therapeutics AG | Drug delivery vehicles and uses thereof |
US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
EP2117305A4 (en) * | 2007-01-26 | 2011-03-30 | Univ Louisville Res Found | MODIFICATION OF EXOXIC COMPONENTS USED AS VACCINE |
JP2011524164A (ja) | 2008-06-06 | 2011-09-01 | サントル・ナシオナル・ドウ・ラ・ルシエルシユ・シアンテイフイク(セー・エヌ・エール・エス) | 小分子rnaに基づく治療および診断ならびに小分子rnaの実験的研究におけるエンドリソソーム系および分泌小胞(エキソソーム様)の用途 |
WO2010141716A2 (en) * | 2009-06-05 | 2010-12-09 | Mayo Foundation For Medical Education And Research | Methods and materials for diagnosing light chain amyloidosis |
WO2011002239A2 (ko) * | 2009-07-01 | 2011-01-06 | 주식회사이언메딕스 | 포유류의 유핵세포에서 유래된 마이크로베시클 및 이의 용도 |
AU2010268367B2 (en) * | 2009-07-02 | 2016-10-20 | Ith Immune Therapy Holdings Ab | Exosome based treatment of cancer |
ATE545193T1 (de) | 2009-07-02 | 2012-02-15 | Converteam Technology Ltd | Steuerungsverfahren für parallel geschaltete stromwandler |
WO2011011733A2 (en) * | 2009-07-24 | 2011-01-27 | The Regents Of The University Of Michigan | Factor replacement therapy |
GB201121069D0 (en) * | 2011-12-07 | 2012-01-18 | Isis Innovation | Delivery system |
-
2011
- 2011-12-07 GB GBGB1121070.5A patent/GB201121070D0/en not_active Ceased
-
2012
- 2012-12-07 EP EP12799264.2A patent/EP2788019B1/en not_active Revoked
- 2012-12-07 EP EP17156973.4A patent/EP3192526A3/en not_active Withdrawn
- 2012-12-07 CN CN201280060627.5A patent/CN104053451A/zh active Pending
- 2012-12-07 EP EP19174981.1A patent/EP3563866A1/en not_active Withdrawn
- 2012-12-07 JP JP2014545356A patent/JP6145595B2/ja active Active
- 2012-12-07 WO PCT/GB2012/053052 patent/WO2013084000A2/en active Application Filing
- 2012-12-07 DK DK12799264.2T patent/DK2788019T3/en active
- 2012-12-07 ES ES12799264.2T patent/ES2625863T3/es active Active
- 2012-12-07 US US14/363,685 patent/US11103586B2/en active Active
-
2017
- 2017-01-05 JP JP2017000739A patent/JP2017119701A/ja active Pending
-
2019
- 2019-09-17 JP JP2019168435A patent/JP2020023503A/ja active Pending
-
2021
- 2021-07-20 US US17/380,388 patent/US20210346504A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003531864A (ja) * | 2000-04-27 | 2003-10-28 | アノシス・インコーポレーテッド | 膜小胞を生成する方法 |
JP2006518219A (ja) * | 2003-02-18 | 2006-08-10 | マックスサイト インコーポレーティッド | 電気穿孔法による細胞への抗原の負荷方法 |
WO2010119256A1 (en) * | 2009-04-17 | 2010-10-21 | Isis Innovation Limited | Composition for delivery of genetic material |
WO2010126081A1 (ja) * | 2009-05-01 | 2010-11-04 | 株式会社メディネット | 不溶性蛋白質及び/又はペプチドの可溶化方法 |
Non-Patent Citations (5)
Title |
---|
BIOESSAYS, vol. 33, no. 10, JPN6017038022, October 2011 (2011-10-01), pages 737 - 741, ISSN: 0003889109 * |
BLOOD, vol. 113, no. 12, JPN5015001820, 19 March 2009 (2009-03-19), pages 2673 - 2683, ISSN: 0003889107 * |
INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 5, JPN6016015959, 2010, pages 889 - 900, ISSN: 0004028046 * |
JOURNAL OF IMMUNOTHERAPY, vol. 26, no. 5, JPN6016015955, 2003, pages 440 - 450, ISSN: 0003889106 * |
NATURE BIOTECHNOLOGY, vol. 29, no. 4, JPN6016015957, April 2011 (2011-04-01), pages 341 - 345, ISSN: 0003889108 * |
Also Published As
Publication number | Publication date |
---|---|
CN104053451A (zh) | 2014-09-17 |
US20140356382A1 (en) | 2014-12-04 |
JP2015500825A (ja) | 2015-01-08 |
JP2020023503A (ja) | 2020-02-13 |
US11103586B2 (en) | 2021-08-31 |
GB201121070D0 (en) | 2012-01-18 |
EP3563866A1 (en) | 2019-11-06 |
EP3192526A3 (en) | 2017-08-30 |
JP6145595B2 (ja) | 2017-06-14 |
US20210346504A1 (en) | 2021-11-11 |
EP2788019B1 (en) | 2017-04-05 |
EP3192526A2 (en) | 2017-07-19 |
WO2013084000A3 (en) | 2013-10-10 |
EP2788019A2 (en) | 2014-10-15 |
DK2788019T3 (en) | 2017-06-19 |
ES2625863T3 (es) | 2017-07-20 |
WO2013084000A2 (en) | 2013-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6145595B2 (ja) | バイオ医薬の送達のためのエキソソーム | |
US20180030153A1 (en) | Compositions and methods to modify cells for therapeutic objectives | |
JP2021523110A (ja) | 遺伝子発現のためのナノ粒子及びその使用 | |
Michels et al. | Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms | |
US20230203532A1 (en) | Recombinant polypeptides for programming extracellular vesicles | |
US20140348904A1 (en) | Exosomes With Transferrin Peptides | |
KR20150010699A (ko) | 적혈구 결합요법 | |
US20230312745A1 (en) | Modular platform for targeted therapeutics | |
Chuang et al. | Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications | |
EP4309677A1 (en) | Pd-l1 and tlr7 double-targeting nanobody coupling drug and use thereof in anti-tumor | |
JP2023544970A (ja) | 細胞への核酸の送達のための組成物及び方法 | |
Śledź et al. | In situ programming of CAR-T cells: a pressing need in modern immunotherapy | |
WO2023179789A1 (zh) | 干扰趋化素样因子超家族成员6(cmtm6)表达的基因治疗载体的制备和抗肿瘤应用 | |
CN107556386A (zh) | 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用 | |
CN114380907A (zh) | 靶向cmtm6的纳米抗体及其制备方法和应用 | |
CN117018217B (zh) | Gnai2作为细胞外囊泡支架蛋白的应用、细胞外囊泡及其制备方法和应用 | |
US11844824B2 (en) | Nucleic acid molecules and methods of using the same | |
WO2023215560A1 (en) | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) | |
Huang et al. | Advances in targeted delivery of mRNA into immune cells for enhanced cancer therapy | |
WO2024050551A2 (en) | Compositions and methods for in vivo expression of chimeric antigen receptors | |
WO2013117735A1 (en) | Conjugate comprising an agent and an antiviral ligand and its use in a method for delivering the agent intracellularly | |
WO2023069971A2 (en) | Cd24-loaded vesicles for treatment of cytokine storm and other conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170203 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170203 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171010 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180410 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181002 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190402 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190514 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20190920 |